CHRS - Earnings call transcript Q1 2024 | Coherus BioSciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to Coherus BioSciences, Inc.

First Quarter 2024 Earnings Conference Call. [Operator Instructions]I would now like to turn the conference over to Jamie Taylor, Head of Investor Relations. Please go ahead.

Jami Taylor

operator. you, Thank welcome Conference and BioSciences Quarter First Good to Earnings Call. XXXX afternoon, Coherus

are today results our Interim Joining Chief discuss that Coherus' Officer; I'd These Commercial to me our Chief Dias, Officer.Before of remind of headcount, Paul you our today's limited but current statements about our Medical to forward-looking advance Bryan regarding we debt call and following, Officer; Officer; like statements started, Rosh Executive future Theresa the are Coherus; McMichael, events. expectations Development Financial our future LaVallee, include, to Chief expenses, our not and to, includes Reider, levels. growth, ability Chief Chief revenue, Officer Lanfear, Denny projections get pipeline,

forward-looking risks forward-looking and beyond risks not these statements of achievements uncertainties release clinical cause press results, drug documents substantial file SEC. the involve subject control guarantees our to that in the inherent today, well future differ our process and performance, statements in as with and uncertainties by and statements.These are to implied substantial we as actual discussed the are are we development or could in issued that and performance are of those that that risks including from the All uncertainties,

I'll no on call call the undertake or provided to duty of statement.And turn we today Denny. the and update now, statements any this Forward-looking are made over date as revise to forward-looking

Dennis Lanfear

everyone, our today. call you, and you on us Jami. thank Thank Good for afternoon, joining

me emphasize open X let things. As we the call,

commercial our aware, the FDA XXXX, received are initiatives and results success.As fourth quarter our secondly, products you successfully portfolio. US are First, strategic in the strength quarter long-term first X for executing for position to for of vital we of approvals we company our the

opens features company's only delivery therapy. the launched nasopharyngeal injector, with last that X on leveraging our for oncology. previously market products, access.In novel innovative focus we rare it the from of derived the drug an a large which mechanism FDA-approved portions months, UDENYCA up And LOQTORZI pegfilgrastim synergies is for that devastating we carcinoma, and not cancer the on-body both could First,

Chief moment, quarter.Recently of Officer, both you with been are detail, share launched enthusiasm with products will more each launches the cancer this describe patients. to company's our these of growth Our in survival products a innovative and Commercial market just Reider, extending have in the has and revenue the received fully aligned experienced mission Paul which

to financing, was divestiture the interest and transaction just we the debt, and while Rosh inventory. the to million cash asset how reducing $XXX in and data term value for cash This costs, remaining down fully With to Dr. upfront our On us which the first large side, products.And now to in term dimension, sheet Across development announced I'll and moment, $XX consistent more this loan the remaining date non-core, no recent executing balance medical for has X million describe shareholders plan.Regarding Coherus' advancing X debt improving our additional completed, new plan, our well developments.Early our to key Dias, our we period, to at the have R&D X-month gross million which the an years particularly over million, debt XXXX. October due margins.Today, mission. for million call development non-dilutive we and recent will maturity.Timeline initiatives, pay announced just allowed we structure, with structured plus pipeline progress Paul consistently and our Paul? with strengthen in over Theresa overhead with company let LaVallee of is me impressive Dr. out a our costs, major that, presented enhance company's we the and are moving headcount debt extends significantly highlight loan beyond long-term come. for every been CIMERLI, strengthening strategic the the to by due to reducing our divestiture demonstrated, royalty optionality $XX.X XXXX XX% of conferences the of turn a maturity under in and the is otherwise focused agreement is commitment steps capital of strong that made. portion $XX.X have while exercising on a with repays of strategic Reider. where horizon This $XXX springing the this has reduced a quarter, relevant and non-oncology payment,

Paul Reider

Thank you, and Denny, good afternoon, everyone.

organization divestiture, ophthalmology oncology which commercial The focus top UDENYCA our now supports ONBODY, ongoing driving autoinjector, are enable the objectives. line business we like, singular oncology-centered launches UDENYCA an revenue. on LOQTORZI, overarching With

plan. executing to We are

over pleased XXXX. QX the with Total progress.Regarding a We million, our $XX.X product are quarter's revenue performance. net increase XXX% was

$XX.X oncology expectations early net an XX% and momentum accrual building. patient a in was revenue new XX% XXXX.LOQTORZI and For launch over in million with in with UDENYCA and quarter, million, QX the quarter-over-quarter our line still brands, revenue $X increase net core QX increase was our

now CIMERLI, February.I'll was oncology the in of Now products.LOQTORZI the combination pipeline on in about was for reflects March unresectable or as chemotherapy.Today, CisGem core serves metastatic or has NPC, revenue upon is approved single-agent for for foundation adults care for with progression and first-line with or immuno-oncology as $XX.X therapeutic more recurrent metastatic a with our platinum-containing starting net recurrent of net our adults and with label with establishes quarter YUSIMRY million January commercial a the only revenue the broad commercialize standard exciting assets, sales non-core advanced with treatment which I/O will the speak And chemotherapy. QX detail a we locally Coherus our on NPC $X.X disease is and after LOQTORZI of of deal million, products, area, growth launch finally, Xst, for XX% given quarter-over-quarter. LOQTORZI. for now in and The closed

prescribing only ambition necessary greater survival in final course the LOQTORZI first-line national NCCN, these the new plus on LOQTORZI of remain scheduled. formulary fee been in is hospitals, of treating plus.Second, chemo of and affirmed launch, XXXX lives the than and LOQTORZI with has payer in as for oncologists NCCN, our plans.Third, with as institutions overall NPC data of academic top X LOQTORZI designation leading priority, beyond. now NPC the regional a including institutional the plans, have from LOQTORZI we've commercial confirmed and hope of it's the on XX% Clinpath XX% advocacy nation's NPC survival the NCCN highlight standard clinical and in preferred achieved is was coverage in the second chemo and results care on X trial of to offer chemotherapy new leaders Medicare line of enable top by over a data and and versus reduction Medicare Advantage, among risk broad who XX% alone.Educating based position examples.First, milestones reviews care.Since clinical amplified the the being the standard which its use the health remaining on of series the added benefit the and medical LOQTORZI Category establish XX research and the for for resulted PD-X of In service, plus to to ASCO JUPITER-XX patients the death regimen guidelines. So I'll a was greater the included only strength opinion

to is J This product-specific processes by LOQTORZI addressable X, we Formulary permanent conversion more end a NCCN XXXX. and enthusiasm, The launch market the patients all efficient opportunity delivered expected for Code turning to fueled has monotherapy, estimate progressing which UDENYCA. Based by with the driven product, we're of of for will combination UDENYCA to CMS our enable patients is July across embracing all with is hospital X speed building XX execution. plan.Now, X,XXX quarter formulary fall line of within execution by will will approximately institutions indication, be the as position QX underway, billing revenue the community reimbursement lines take providers. pleased continues.In is We're momentum or highly strong therapy, on the chemo with to as strength launch in LOQTORZI labeled drivers. expectations. was growth time treatment process LOQTORZI's by XXXX.Finally, continued achieved which been the that another granted the with approximately our with effect QX, received the

nearly state-of-the-art compete across First, demand coverage, XX% the of to allows XXXX X than key for price.Third, patient and system the us to brand XXXX, pegfilgrastim performance significantly device competitive to commercial pegfilgrastim, patients. market.Second, on the UDENYCA only strengthens Xx the up launch of and a pre-filled our UDENYCA for auto-injector into now pegfilgrastim for grew driven payer to other access opening providers entire the needs we more quarter, the unique with that This come by UDENYCA syringe UDENYCA novel ONBODY, enabling and is with presentations. franchise meet primarily of position proprietary lives.As indicators factors options quarter-over-quarter, compete delivery

market share an XX%, increase In points XX share market was addition, franchise quarter-over-quarter. of

growth to Regarding the X-minute solution, with to into which launch and as of patients we franchise focus our Onpro. on now differentiation delivery strong a is in injection and UDENYCA been UDENYCA over call and this course very is noted XX% receptivity Medical is a Officer. time, improving adoption.Summary, revenue providers Dr. are Dias, Rosh? differentiator, expect continued the approximately customer now Rosh of Neulasta key ONBODY positive.Specifically, medication has offers and This faster the turn UDENYCA pointing ONBODY total customer margins Chief XXXX.I'll translating unit providers the

Rosh Dias

Paul, afternoon, a a of in survival form foundational together portfolio. immuno-oncology published efficacy Thanks demonstrated continues to with of sets profound types, carcinoma, tumor or across data very positive the element and additional LOQTORZI much, with our toripalimab variety advantage nasopharyngeal everyone. good

start further with cell subjects this first combination year opportunities study HCC where data registration by in next toripalimab the funded the this the will plans, types.Firstly, Phase of further year.Our progress targeting recent Theresa carcinoma of development head efficacious the respect track and INOVIO yesterday disease endothelin with compounds respect our lung into looking CCRX exploration as earlier excited we serves cancer-led squamous squamous of our lung progressing cell lung with now partner, We stage casdozo us is B which about demonstrated with out U.S. and to that IO Phase they delighted from we've toripalimab currently combinations.Finally, novel data have abstract companies backbone affords currently by good of multiregional with strong.We're linkage highlight antibody novel the example also portion according with detail of non-small with through in INOVIO a act highly to II earlier to head BTLA we strategic actively as combination the escalation where cell where the registration toripalimab Cancer our addition, a by opportunities for such variety wider internal presentation with the announce combinations, towards in also vaccine trials studies, internal particularly and tumor fully in the of distinct phase tightly patient as of non-small been status data combinations accepted to potential as as provides PD-X, a population we platform pipeline, Innovia next with has compounds remain let year to cancer head speak with in continues advanced escalation term HPV-positive strategies enabling registration upon respect Phase have advanced of approved own in limited refractory targeting stage utilizing small with where is competitively partnered end underserved study development and III at about or all which selected validation on III our of toripalimab an PD-X foundational as partner novel and response casdozo are ASCO remains opportunity Research excited study in by in neck on Institute in cancer, continues antibody, are and development.In Junshi our afucosylated and by is studied ongoing ASCO of As US IL-XX program toripalimab further Dr. carcinoma casdozo. LaVallee, promising active antibody, for the therapeutics over dose With continued this the potential track been programs CHS-XXX, approach partnership with novel squamous further have which Chief where combination EMV at Officer. first-line both the areas that earlier where in toripalimab overall were historically data also casdozokitug early opportunities cell will partner. an that X year, for has and in to with at PD-X within and registration-enabling providing that exploring backbone the other for forward toripalimab we trial. now thirdly, second company a make the of immunotherapy.Selection the the lung in NTT.I'll to carcinoma, the cell progress CHS-XXX, Development GI.Turning investigational with demonstrated toripalimab stage prosecute sites. setting.We're are is for of combinations cancer.And setting, opportunities, carcinoma, and call development PD-X in study locally study our inhibitor development the rates the an Junshi encouraging the anti development the to report outside small dose III plan CRI we're was for program study building the with of time cancer meeting.Next, activity advanced in remain to And this well-positioned expansion in our our and few an ovarian PD-LX and that neck, element that to ongoing of me CCRX consists novel cell of the to Theresa? on weeks' in this a assets, study pipeline, in in for ILTX.Secondly, neck our combination presented BTLA-toripalimab nearer-term the limited these sponsored X companies cell focused moving partner turn taking our our stage half pivotal data supply by our presented ILTX in the monotherapy start hepatocellular advanced to for more AACR our to Phase to second INOVIO

Theresa Lavallee

our our Rosh, and afternoon, pleased or on additional Thank update progress and efforts I'm you of pipeline. pursue microenvironment, to you, good TME, tumor to everyone. focused development

We on clinical December have in XXXX immune broadly HCC presented clinical non-small development combination with in with and have demonstrated LOQTORZI.The cell were casdozokitug plans studies. X in focused January XXXX activators efficacy combinations in partners, cancer approaches, clinical with data the internal and lung early that

for in approved cancer Scientific anticytokine Immunologists Chicago multiple the and not Importantly, IL-XX diseases drugs further, but Dr. this and exciting. IND-enabling with response biology psoriasis, and Hunter NK as and the lung was studies the basic on effects American IL-X IL-XX how Coherus equal he show team and activation AACR that his a cancer for and and translation Advisor, a indications The immune favorable immune plan.I'm It lecture for of safety lower profile, show focused presented in with the has the and T our dysregulated are on lung, and say well rheumatoid lending absence IL-XX cancer. casdozo also a is IL-XX XX per in development proud where of tissue. immune work casdozo recent of diseases.Our cytokines, importance, results Christopher at of to critical tumor mouse cells.Interestingly, the of T allows has notable as strong NK X. in is with to mg combination for and regulating studies drug regulatory that line of X from liver sight have in system of of FDA in of We the immune first-in-class. activated or XXXX CHS-XXXX. Association internally research IL-XX, to Casdozokitug family antagonist on our the ILTX these casdozo the IND treatment to activity discovered very higher, are to developed described track that remain inhibited IL-XX, successfully for IL-XX is disease, the system, most of University demonstrated cells per doses liver, approach study, Pennsylvania, showing antibody CHS of casdozokitug In feedback inflammatory models Phase XXXX.I'll or cancer at been mgs Dr. the which pathology bowel an call immune antitumor in May and lecture, is first of IO kg distinguished is in antibody McMichael. activated.While inflammatory on IL-XX, rebalancing role at treatments overactive is cells second antibodies Congress brain this research treatment understand patients In established arthritis, honored blocks quarter not yet the the an for candidate. due the is turn family in Hunter's signaling inflammatory such at data kg and In to patients. specifically I Bryan now immune meeting, biomarker

Bryan McMichael

Since Theresa, Denny will million. $XX.X rest capital Paul to covered the P&L cash.Cost afternoon, and QX structure you, Thank and everyone. the goods the updates and of was good of revenues, I on sold focus XXXX during covered our

from the million Excluding a COGS of the year net write-down costs XXXX is Surface or write-off share, pipeline.SG&A and biosimilars loss obtained million Novartis $X.X diluted million reduced per was income $XX.X XXXX.Non-GAAP of was on QX partially that share equivalents to or with million a decreased from were with net primarily for the a million Novartis.For compared net of terminated compared the $XX.X year-end. charge million per loss driven associated XX, which $X offset share or compared to diluted by $X.XX mentioned QX, license ago, non-cash of QX QX per share reported charge in quarter by excludes in net our $X.XX and $X.X the X% $X.X million same in acquisition securities QX divestiture March associated to same the XXXX. XX% XXXX, by now Oncology in impact IO have reduced increased the from development or in which million decreased the the XXXX and to XX%, in we R&D would first investments NZVXXX, period from in headcount $XX.X on gain reflecting investments inventory and million at as $XXX.X marketable XXXX.Cash million, diluted of share for diluted earlier, $X.XX per share net $X.XX XXXX, in termination and $XXX.X per cash period the or $XXX.X savings and

As This noted expenses quarter pay back the $XXX million business compensation to I Denny SG&A and development that, range includes $XXX of our the million in on earlier, of we million. of activities.With approximately call to over ended.Today, reiterating turn guidance after $XX XXXX other and closing million used we remarks. for R&D are $XXX will stock-based cash principals and the to hand expected combined unforeseen excludes activities

Dennis Lanfear

you, Thank Bryan.

emphasized executing are value. to remarks today, have on we X-part throughout well we our our plan shareholder deliver As

secondarily, line and the our our operating top driving of controlling First, revenues expenses.

of We for focused as to improving are I'm open our as questions. making fully happy in I are our structure. and, an company.Operator, great oncology lastly, now we the and line microenvironment disclosed, progress progress of confident we're both innovative charted the have tumor we pipeline making advancing course, capital assets

Operator

line comes from Citi. the with Your first Nochomovitz of question Instructions] Yigal [Operator

Unknown Analyst

a new bit Ashley if to I how wondering thinking that so moving little look is assume the going you towards about each contribution This quarter? Yigal. for Mubarak more but presentations, late, I'm to importantly, thinking that presentation I on [ I revenue you're how's the of for apologize this, will And I but how the mix forward? joined it. increase missed UDENYCA are of weighting the of ] about coming kind like

Dennis Lanfear

market. question. for that Thank Paul presentations have your be you further very will happy to on the X Paul? much contribution we revenues for the Reider now describe the

Paul Reider

Yes.

came quarter, still mid-quarter. It around in X%, syringe the mix. our the X% The that, is ONBODY prefilled share in around largest SKU the and autoinjector first the XX%. -- launched represented recalling So we was of the around

we of the had quarter about ONBODY. So half of the only

So bit a that's varies the segment. mix.It SKU breakdown of the little by

each that hospitals exactly competitively to patients market for options works see that patient could So individual different which tend them, pegfilgrastim.So XX clinics unique only positioning share points XX%. we're you we translated or X deliver to the and the now how they into best is franchise how differentiation meet quarter-over-quarter the the ] and can needs offer has And how customize percent growth. of [ franchise. to are providers SKU that

remainder we're the drive as year unfolds. going that continue to And differentiation to of the so

Unknown Analyst

the of Paul, rest how share each the you of line the of on do sight Do evolving market we any the have presentations see of year? through that?

Paul Reider

Yes.

still it's think launch. early in I ONBODY the

where a the are the moving right hospitals. to with I from injector it's to least, would But growth been segment. mix, we prefilled also in. clinic in clinic in can So We segments fitting see year. the has this I being gaining good now still year, syringe it's and expect the segment the the tell percentage largely feedback the ONBODY the that as you auto the think primarily different But continue at remainder holding going that ONBODY. throughout of customers SKU and throughout still of we're

Dennis Lanfear

you question. your Thank for

Operator

the from comes Securities. with Kripa Devarakonda Truist of line question Next

Kripa Devarakonda

a on LOQTORZI, launch the it's on For has drop some line maybe well. new been more going you And line and mentioned Can also, launch I -- in you provide relatively think color disease. that used second rare it's or the front setting? whether is

to on So it take can you get mentioned formularies. time the

about XX% Is line of being -- on XX% in expectations? NCCN this your with the You XX talked hospitals.

Dennis Lanfear

utilization the NCCN line comment bit thank for frontline versus your and XX% Paul be Paul? little Kripa, conversion. happy would you question. about to a second

Paul Reider

your Yeah. for question. Thanks

new second if being both advanced typically, in contribution both What be the are these back also will with of and on large of as as those build It all the in remaining completed for going majority LOQTORZI, LOQTORZI with the with duration line chemotherapy. by thing, year. in indication when the line the institutions is And was of patients, in it's line in recurrent the It's in the our and up frontline takes to those more line to PD-X, value it's we and was seeing when uses. the we we later throughout combined mentioned would go and plus.So, in and combined in therapy, less. The centers this, it's positioned patients to being lines like our have yes, be the patients' earlier use with frontline that's franchise the difficult it we JUPITER-XX expected, much And that cases, indication of X think frontline, all the eligible formularies, over second as NCCN we locally the medical metastatic And labeled likely expectations. through consistent already expected, indicated will plus. setting of end LOQTORZI I the chemotherapy trial an to the the of the if indicated standard when going the LOQTORZI labeled be you or monotherapy the those patients. expect as only time to setting.As for saw, that though, was very off-label it's So, processes. in those mentioned, the stage in the second have case, I of that as years capture.So, occur Academic care formularies. next are

Operator

the Cowen. from TD with of line Nedelcovych Mike comes question Next

Michael Nedelcovych

have I X.

also The first on is LOQTORZI.

needed is question education any Is be the is off-label to So, prescription that then done question.And that's basically additional gaining work residual access on lever checkpoint be there to marketing impressive. a second pulled in in X Or needs other my displace YUSIMRY. of that's from perspective? physician Your or is inhibitors? progress formulary that order to

outlook? I be think you year IRA YUSIMRY have Or a could Are that provisions. YUSIMRY's for like thinking that about what on some a the suggested it on still XXXX YUSIMRY of based way? Does future you've the in thinking your ahead? biosimilar is latest past bright an inflection

Dennis Lanfear

the Dr. LOQTORZI, I'll Dias question. Paul that have Great. the Rosh Thank Rosh? the you and let therapy address for YUSIMRY. talk secondarily firstly of then physicians with selection of the can about now issue decision launch

Rosh Dias

for much Thanks Yes. very the question.

So, and to pretty have evidence-driven X that we I no other PD-X tend be say would has. doctors things

all, of have an First we indication.

a third a have of first-line other thing PD-Xs survival the the reduction trials advantage we positioning the have preeminent nasopharyngeal on of context setting, negative risk NCCN. carcinoma.And we also the in in And in XX% profound death. is again, Secondly, that's then with

line, the we line -- we beyond, second X have the we are actually. regimen, the therapy first category So, IO only designated preferred and only in and are

So start message continuing and Paul's these seeing key, I things X think are we those I think is as patients, to team things. on X

Dennis Lanfear

Thank you. Paul, going YUSIMRY do to bit for on our IRA? little expectations you want to comment with a XXXX

Paul Reider

ongoing. Sure, Mike? YUSIMRY negotiations Yes, are Denny. Thanks formulary for are in and for your question, XXXX And Coherus actively engaged that process.

see in be even space. So we the the biosimilars of the greater think, where we that inflection continue I point will believe that to -- adalimumab

well-positioned price product I the value patients. our brings So to care health based the and point systems there on this and we're think that

Operator

with from last the Your comes question Prasad Instructions] [Operator Barclays. Balaji line of

Unknown Analyst

on Balaji. This is [ Shau for ]

they Just licensing autoinjector, there in first and are to that are are Amneal that ONBODY injector to pre-filled BRA announced the other expect pegfilgrastim quick question on get follow-on this UDENYCA of submit they a and [ landscape. recently quarter trying franchise. ] XXXX. into a few And the players

landscape to defend X those new you plans entrants? mechanism ONBODY the build and your for injector have the next or the shares potential do And market entire against is any what to expectation your market years? X pegfilgrastim and So for

Dennis Lanfear

Want the pegfilgrastim your with to market respect entrants you. to with a question having -- I'm difficult sorry. or future in with hearing Want the understand time question. ONBODY Is we're to your understand autoinjectors? space

Unknown Analyst

ONBODY first in in Pegfilgrastim auto they that and injector market, recently have pre-filled BRA injector plan of file something quarter -- to XXXX. as a plan like -- the they especially and Amneal the announced auto-filled

Dennis Lanfear

how to future the we you market for view address would competition pegfilgrastim like in Paul, autoinjectors?

Paul Reider

Yes. here. we've leadership pegfilgrastim maintain now Well, of sixth in market all and first of we're one year -- been our in the operating positions this

business our and the we're to So this, tried payer what And presentations. because coverage. X the to and and is solution going as well I strong be is on and UDENYCA, we're established all got mentioned, doing which providers got for patients. focus we've continue we've positioning market.Secondly, true total the to of today, It's do in

that's UDENYCA all to brand is we of marketplace, these brand. and quality by high the because of also predictability, that that And the reliability only not being recognized consistency this but brand bring go-to the so a benefits the in payers

we that compete any win, if whatever So But landscape believe prepared else and comes. anybody we'll well-positioned continue to unfolds. competition be for be we'll to

Dennis Lanfear

Thank you, Paul.

a make point The the approach, sophisticated And hurdles device our an time. We very the we need the market, X technical novo, market, received due innovative approaches consistent are investigated market. said, which we settling and are last presentations, pegfilgrastim the and it there patients lastly, by that right. an the represents is X only important. number X-minute the injection track highly is and we demonstrates in all filling We the Paul competitors got one.So a team significant injector been I with to is particular that. believe as are our physicians with of with years in enthusiasm a this this de we other But we remarks, first record think Paul's each would before the to on think has it that ONBODY with over such

share in our compete I ability that this believe to and market. successful we're remain and So in very confident grow

Operator

line the Wainwright. Douglas from with comes question of Tsao H.C. Another

Douglas Tsao

those gates have can particular, terms a the you need you -- sort there of clear -- at the to need do -- number we of an acceleration to sort get to ramp-up getting for of that the think Obviously, steps revenue How through in in quickly And majority clear to LOQTORZI on you the see most and of what think access formulary. do trajectory? market? you we to are you the start need might really might of other before of in sort of

Dennis Lanfear

little your on you adoption we for Paul, question, Doug. bit comment the LOQTORZI of do like Thanks the to that? would of how a and gating

Paul Reider

Yes. Yes. your Doug. Thanks question, for

on hurdles foresee I payer really the the -- is first that's further So, one, And side. was well payer obviously, the coverage and don't established. any

second ensure of the order have guidelines, now each accounts The is that now is what we've into sets. that we to translated the guidelines the gate are in that got NCCN the

ongoing, this up, next again, that typically chemo sort prescribing combination continue they when and oncologist disease. the effort here I there. click That's we're the of team, which set to feel going doctor efforts.And our in next time gate through really the and decision, going at again, LOQTORZI just It's deploy the of networks, chemo is referral terms is that of enables but in the that digital going is the LOQTORZI, to but that. think settle over those that Doug, this KOLs will order on to So sales through out all from year anybody a treated podium promotion, and a that we patients and as PD-Xs LOQTORZI around with the And washing ramp off-label or to not achieve peak choice think so from a through going new X with to at we're that's start chemo PD-X is to and through of current on the the But patients. on invest going establishing continued knows just why occur the is the getting current the of confident the take very it's that's this. LOQTORZI. that are new we of regimen both today rare patients quarter.Then, also time But for our those of

Dennis Lanfear

of Paul for year market around and elucidated, steady share this X. ramp reasons out probably a up growth Doug, as the peak the that just see market to all we penetration,

So in them. patients just and patients them immediately such a get various These stages or the something another Those therapy. exposed find on enzyme They'll going have are They benefit. all patients you replacement are convert PD-X. isn't market as chemotherapy. can catch these We're a of out that market eligible. are where all to may to been this to

of but the Rosh I over future. well blocks have second forward market, Some a for from gotten line. the the We've are to Dias them patients, the for is, key see therapy very, the position formularies. FDA. the pointed very all steady with as with a But are in the doing would ramp out, we first-line we we on will issue progress wait only We're place building to the to NCCN, say

Douglas Tsao

uptake terms starting of versus patients autoinjector. any Okay. types. Are a getting of auto-injector to of if are as that the the using just we're see have themes the vice types are versa? just And product maybe device franchise. dosage I'm X Great. how you the the of follow-up curious as both in terms sort UDENYCA the ONBODY question physicians ONBODY and or -- of curious, those X well there of forms your on in I'm insight

Dennis Lanfear

I Paul, sort on. the settings what the what for of is, patient for go guess and they the would so settings ONBODY autoinjector, patient question

Paul Reider

Doug. Yes,

a let So in of this couple frame ways. different me

clinics. the take let's First,

going to connectivity come of have with next the with more They their So the towards X nurse gear who office are all the back patients the like and the because clinic they presentations to day. high-touch like their segments doctor. to

injection the But the autoinjector are time clinic, therefore, positioned they give of want device option patients patients. X-minute the with the under home. and themselves And patient they inject in the their choose them Therefore, prefilled to some at so well-designed can self the or not syringe and experience for wants they injection.But ONBODY we at the those XX the wear like. a place seconds and if device, inject, that auto-injector the

we're they with the bit really ONBODY go the syringe. positioning that's a hospitals, patients provider. or more to So and prefilled little The how the by device by tend the

the the nearly much at-home autoinjector with we've the clinic, in syringe they So prefilled uptake but ONBODY as good is in either hospital, preference. the had because or not the prefer

we're the differentiation. franchise of that us seeing market being share all So only really a competitive think that's And with apart kind I X it.And, in growth. options sets you see our from how

Operator

with comes the Baird. of line Colleen Kusy Question from

Colleen Hanley

for for ONBODY? Just thoughts autoinjector? growth is UDENYCA flow goal focusing set I of towards So point, prefilled but to just and remarks, reaching on you growing will -- still the around and the the kind syringe prepared if for it XXXX. just guidance missed be just cash it growth this for XXXX? in Is realizing think year. about drivers UDENYCA in if you're that Is if but what the speak the providing positivity at not And potential this this sorry could of how then,

Dennis Lanfear

and with let handle I'll I'll UDENYCA then Paul respect handle drivers first, growth to your Thank XXXX. question secondary the you, for Colleen. Paul?

Paul Reider

Yes, thanks our for your fully question. be the of XXXX. to Yes, predominant growth we I in ONBODY expect the driver think

As market penetrate syringe presentation to the the product prefilled really that market been presentations. difficult now the Denny coverage our autoinjectors.So this that It'll which segments growth mentioned and I for payer was up that of payer year. that drive with we're that mentioned of looking opens approval to that have year. year share all of for the and doubled product versus last extends And buoyed our to be coverage, X remainder facilitated SKU, by

inhibited each by coverage really presentations. payer So, not of by those

all So, will where as we've X we've it, we got execute. leverage continue to and got we that

Dennis Lanfear

had Paul. got approvals. lot With secondary than the is XXXX ONBODY launch the of the autoinjector the I getting would we -- predictable that time. went LOQTORZI We was LOQTORZI. successfully. on of particularly that more the a little of the that rolled to got launch We XXXX, Thanks, focus then up approved and now And a That to took question, into We we a respect year FDA. approval. XXXX. did to launch and launches, done. We getting say and your be on first focused shaping Insofar ONBODY, the

issue trajectory year experience, growth the are revenue what right. we'll steep backwards, curve the is UDENYCA is by the continued be, continued will much reasons growth. as also that is go growth looking how see for constrained Paul believe looking just that how So out. growth.We'll laid we XXXX like, with that And The we the real world we quarter-to-quarter. respect -- to on more see over And LOQTORZI

We very in are these launches. early

gotten to a We good very LOQTORZI, we're making it's but the have progress out formularies, on just disease. respect there. With rare

to Now the off start. acquire think to on. and a patients we I good very we're have so But

to want in move we forward will is But up. our it's that forward looking, to I a go in growth question growth will although remains we're So how happy don't very to continue.So clearly, that forecast and is sights that of clearly direction. indicated, with. as our when something respect the That with

Operator

There call this are no time. over you. Lanfear, further I Mr. questions back to turn at the Dennis

Dennis Lanfear

the progress you microenvironment And our pipeline. pricing our overtures, us made you look operator. advancing particularly for with you, our respect to you. call. today. across Thank to ] you our for tumor to for driving next focused we progress of we've forward at Thank the on opportunity our our enumerate [ Thank all And sales all call thank joining you of key and

Operator

today's call. conference Gap] [Audio

You may now disconnect.

Coherus BioSciences (CHRS) 9 May 242024 Q1 Earnings call transcript